CB Insights
Technology Market Intelligence
Technology Market Intelligence
Probiodrug is dedicated to the discovery and development of small molecule drugs against novel molecular targets for the treatment of neuronal- and inflammatory diseases. The company develops therapeutics to treat diabetes and is now applying its exp...Show all
Company (IPO / Went public)
Phone: +49 345 555 9900
Weinbergweg 22
Halle, D-06120
Germany
| Total Funding | Date of Last Funding | |
|---|---|---|
| Probiodrug | $142.5M | Nov 3, 2014 |
| See all 42 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Uses of antibodies directed against amyloid-β | Sep 03, 2015 | Jun 13, 2017 | Patent |
| Diagnostic antibody assay | May 19, 2014 | May 23, 2017 | Patent |
| Inhibitors of glutaminyl cyclase | Apr 18, 2008 | May 23, 2017 | Patent |
| Inhibitors | Sep 23, 2015 | May 16, 2017 | Patent |
| Radiolabelled glutaminyl cyclase (qc) inhibitors and uses of same | Dec 15, 2014 | Apr 04, 2017 | Patent |
